We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Mutation Reducing Fatty Acid-Binding Protein Activity Lowers Heart Attack Risk

By LabMedica International staff writers
Posted on 08 Sep 2014
A team of Finnish cardiovascular disease researchers found that a mutation generating a low-expression variant of fatty acid-binding protein 4 (FABP4), reduced the risk of heart attack and stroke. More...


The FABP4 gene encodes the fatty acid binding protein found in adipocytes. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands. It is thought that the roles of FABPs include fatty acid uptake, transport, and metabolism. Earlier studies detected a mutation (rs77878271) in the human FABP4 gene that caused reduced FABP4 protein transcription.

Investigators at the University of Helsinki (Finland) examined the effects of this low-expression variant of FABP4 on cardiovascular morbidity and carotid atherosclerosis in a random group of 7,491 individuals and in patient cohorts. The cohorts consisted of patients with advanced carotid atherosclerosis who had undergone surgical procedures (endarterectomy) to excise the inner lining of arteries clogged with atherosclerotic buildup (n = 92) and those having experienced myocardial infarction (MI, n = 3,432).

Results published in the August 13, 2014, online edition of the journal Circulation: Cardiovascular Genetics revealed that the low-expression variant was associated with decreased total cholesterol levels with the largest reduction being in individuals carrying two alleles for the variant. Obese variant allele carriers also showed reduced carotid intima-media thickness and lower prevalence of carotid plaques. Consistently, the variant allele homozygotes showed eight-fold lower odds for MI.

The variant allele was associated with a 3.8-fold reduction in FABP4 transcription and 2.7-fold reduction in apoptosis in the macrophages associated with carotid plaques. High FABP4 expression in carotid plaques was associated with lipid accumulation, intraplaque hemorrhages, plaque ulcerations and phosphoactivated ER (endoplasmic reticulum) stress markers.

"It could be that reduced cell stress in the stenosis, attenuated inflammation, as well as reduced accumulation of cholesterol and other lipids in the arteries help keep atherosclerosis asymptomatic among the gene carriers," said first author Dr. Jani Saksi, a researcher in molecular neurology at the University of Helsinki. "These findings suggest that FABP4 could be a new potential target for drug development aiming to prevent lethal and disabling myocardial and cerebral infarctions induced by atherosclerosis. The inhibition of FABP4 activity – especially among obese people in the risk group for atherosclerosis – may prove to be an important method for reducing these individuals' risk for cardiovascular diseases."

Related Links:

University of Helsinki



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.